MA38175A1 - Lactames fusionnés à un aryle et hétéroaryle - Google Patents

Lactames fusionnés à un aryle et hétéroaryle

Info

Publication number
MA38175A1
MA38175A1 MA38175A MA38175A MA38175A1 MA 38175 A1 MA38175 A1 MA 38175A1 MA 38175 A MA38175 A MA 38175A MA 38175 A MA38175 A MA 38175A MA 38175 A1 MA38175 A1 MA 38175A1
Authority
MA
Morocco
Prior art keywords
heteroaryl
aryl
compounds
salts
lactams
Prior art date
Application number
MA38175A
Other languages
English (en)
Other versions
MA38175B1 (fr
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA38175A1 publication Critical patent/MA38175A1/fr
Publication of MA38175B1 publication Critical patent/MA38175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Cette invention concerne des composés de formule générale (i), des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques contenant lesdits composés et sels, et des méthodes d'utilisation desdits composés, sels et compositions pour traiter une croissance cellulaire anormale, y compris le cancer. Dans la formule générale (i), r
MA38175A 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle MA38175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
PCT/IB2013/060682 WO2014097041A1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Publications (2)

Publication Number Publication Date
MA38175A1 true MA38175A1 (fr) 2018-08-31
MA38175B1 MA38175B1 (fr) 2018-11-30

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38175A MA38175B1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Country Status (46)

Country Link
US (3) US9040515B2 (fr)
EP (2) EP2935238B1 (fr)
JP (1) JP5909308B2 (fr)
KR (1) KR101712441B1 (fr)
CN (1) CN104870435B (fr)
AP (1) AP2015008574A0 (fr)
AR (1) AR094174A1 (fr)
AU (1) AU2013365908C1 (fr)
CA (1) CA2893339C (fr)
CL (1) CL2015001733A1 (fr)
CR (2) CR20200273A (fr)
CU (1) CU24414B1 (fr)
CY (2) CY1119883T1 (fr)
DK (2) DK2935238T3 (fr)
DO (1) DOP2015000157A (fr)
EA (1) EA028317B1 (fr)
EC (1) ECSP15031579A (fr)
ES (2) ES2808987T3 (fr)
GE (1) GEP201706718B (fr)
GT (1) GT201500190A (fr)
HK (1) HK1208866A1 (fr)
HR (2) HRP20180060T1 (fr)
HU (2) HUE050009T2 (fr)
IL (1) IL239520B (fr)
LT (2) LT2935238T (fr)
MA (1) MA38175B1 (fr)
MD (1) MD4664C9 (fr)
ME (2) ME03793B (fr)
MX (2) MX2015008058A (fr)
MY (2) MY176307A (fr)
NO (1) NO2961649T3 (fr)
NZ (1) NZ708801A (fr)
PE (1) PE20151090A1 (fr)
PH (1) PH12015501367A1 (fr)
PL (2) PL2935238T3 (fr)
PT (2) PT3339303T (fr)
RS (2) RS56815B1 (fr)
SG (1) SG11201504076XA (fr)
SI (2) SI3339303T1 (fr)
TN (1) TN2015000281A1 (fr)
TR (1) TR201802791T4 (fr)
TW (1) TWI546293B (fr)
UA (1) UA111305C2 (fr)
UY (2) UY35225A (fr)
WO (1) WO2014097041A1 (fr)
ZA (1) ZA201504437B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102168621B1 (ko) 2012-12-21 2020-10-22 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2970305B1 (fr) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
EP3033334A1 (fr) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
WO2015193768A1 (fr) * 2014-06-17 2015-12-23 Pfizer Inc. Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
CR20160574A (es) * 2014-06-17 2017-02-23 Pfizer Compuestos de dihidroisoquinolinona sustituida
WO2016066697A1 (fr) * 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
CN111892576A (zh) * 2015-03-27 2020-11-06 先正达参股股份有限公司 杀微生物的杂二环衍生物
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (fr) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Formes cristallines de (r)-n-((4-méthoxy-6-méthyl-2-oxo-1,2-dihydropyridin-3-yl)méthyl)-2-méthyl-1-(1-(1-(2,2,2-trifluoroéthyl)pipéridin-4-yl)éthyl)-1h-indole-3-carboxamide
LT3378859T (lt) 2015-11-19 2020-01-27 Jiangsu Hengrui Medicine Co., Ltd. Benzofurano darinys, jo gavimo būdas ir jo panaudojimas medicinoje
US10604531B2 (en) * 2016-05-05 2020-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3529242A1 (fr) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
US20200262813A1 (en) * 2016-11-11 2020-08-20 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109937041B (zh) 2017-05-18 2022-04-12 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
CA3058496A1 (fr) 2017-05-18 2018-11-22 Jiangsu Hengrui Medicine Co., Ltd. Formes cristallines du chlore libre derive du benzofurane et son procede de preparation
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
US20230012362A1 (en) * 2018-10-24 2023-01-12 Vanderbilt University Wdr5 inhibitors and modulators
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR20200101219A (ko) * 2019-02-19 2020-08-27 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
AU2021203261B1 (en) * 2020-08-13 2021-09-23 Hanmi Pharmaceutical Co., Ltd. Novel dioxoloisoquinolinone derivatives and use thereof
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
WO2022179584A1 (fr) * 2021-02-26 2022-09-01 南京药石科技股份有限公司 Nouvel inhibiteur d'ezh2 et son utilisation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007022280A1 (fr) 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Inhibiteurs de phosphodiestérase 10
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2012005805A1 (fr) 2010-05-07 2012-01-12 Glaxosmithkline Llc Aza-indazoles
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
BR112012028556A2 (pt) 2010-05-07 2014-04-01 Glaxosmithkline Llc Indóis
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012035078A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Inhibiteurs de la 17α-hydroxylase/c17,20-lyase
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012118812A2 (fr) * 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2850570A1 (fr) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methodes de traitement du cancer
WO2013173441A2 (fr) 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
KR102168621B1 (ko) 2012-12-21 2020-10-22 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
LT2935312T (lt) 2012-12-21 2018-10-25 F. Hoffmann-La Roche Ag Peptidai, kaip oksitocino agonistai
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
WO2014096150A1 (fr) 2012-12-21 2014-06-26 Sanofi Agonistes du glp1/gip double ou du glp1/gip/glucagon trigonal
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CR20160574A (es) 2014-06-17 2017-02-23 Pfizer Compuestos de dihidroisoquinolinona sustituida

Also Published As

Publication number Publication date
US20150175572A1 (en) 2015-06-25
EA028317B1 (ru) 2017-11-30
PH12015501367B1 (en) 2015-09-02
CR20150279A (es) 2015-09-03
GT201500190A (es) 2016-01-21
MY176307A (en) 2020-07-28
US9040515B2 (en) 2015-05-26
ES2658974T3 (es) 2018-03-13
EP2935238B1 (fr) 2017-12-27
CN104870435B (zh) 2016-12-07
CA2893339C (fr) 2017-06-13
RS60582B1 (sr) 2020-08-31
MX2015008058A (es) 2015-10-30
EP3339303B9 (fr) 2021-07-21
IL239520A0 (en) 2015-08-31
MD20150052A2 (ro) 2015-12-31
RS56815B1 (sr) 2018-04-30
PL3339303T3 (pl) 2021-01-25
HUE050009T2 (hu) 2020-11-30
AP2015008574A0 (en) 2015-07-31
WO2014097041A1 (fr) 2014-06-26
PT3339303T (pt) 2020-07-30
EP3339303B1 (fr) 2020-06-24
CA2893339A1 (fr) 2014-06-26
BR112015014678A2 (pt) 2017-07-11
US10246433B2 (en) 2019-04-02
CN104870435A (zh) 2015-08-26
AU2013365908C1 (en) 2018-01-25
TW201446753A (zh) 2014-12-16
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
KR20150100823A (ko) 2015-09-02
HRP20201194T2 (hr) 2021-09-17
UY38712A (es) 2020-06-30
PE20151090A1 (es) 2015-08-07
CR20200273A (es) 2020-09-23
CL2015001733A1 (es) 2015-10-23
EP2935238A1 (fr) 2015-10-28
TR201802791T4 (tr) 2018-03-21
SI2935238T1 (en) 2018-04-30
CY1123237T1 (el) 2021-10-29
JP5909308B2 (ja) 2016-04-26
HRP20201194T1 (hr) 2020-11-13
ME03793B (fr) 2021-04-20
MX2020002924A (es) 2020-07-22
EA201590879A1 (ru) 2015-12-30
TWI546293B (zh) 2016-08-21
CU24414B1 (es) 2019-05-03
MY192259A (en) 2022-08-12
AR094174A1 (es) 2015-07-15
HK1208866A1 (en) 2016-03-18
ECSP15031579A (es) 2017-08-31
MD4664C9 (ro) 2020-07-31
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
UY35225A (es) 2014-07-31
LT3339303T (lt) 2020-09-10
CU20150062A7 (es) 2015-11-27
US20140179667A1 (en) 2014-06-26
DOP2015000157A (es) 2015-11-30
ME02980B (fr) 2018-10-20
AU2013365908B2 (en) 2017-07-20
ES2808987T9 (es) 2021-11-29
KR101712441B1 (ko) 2017-03-07
IL239520B (en) 2018-05-31
MA38175B1 (fr) 2018-11-30
LT2935238T (lt) 2018-02-26
US20170233368A1 (en) 2017-08-17
SI3339303T1 (sl) 2020-09-30
ZA201504437B (en) 2016-07-27
PH12015501367A1 (en) 2015-09-02
EP3339303A1 (fr) 2018-06-27
UA111305C2 (uk) 2016-04-11
ES2808987T3 (es) 2021-03-02
DK2935238T3 (en) 2018-01-22
JP2016507497A (ja) 2016-03-10
RS60582B9 (sr) 2021-09-30
AU2013365908A1 (en) 2015-06-11
DK3339303T3 (da) 2020-08-10
CY1119883T1 (el) 2018-06-27
GEP201706718B (en) 2017-08-10
TN2015000281A1 (fr) 2016-10-03
NO2961649T3 (fr) 2018-02-17
HUE038238T2 (hu) 2018-10-29
MD4664B1 (ro) 2019-12-31
HRP20180060T1 (hr) 2018-02-23

Similar Documents

Publication Publication Date Title
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA38138A1 (fr) Dérivés inédits de quinolone
UA111770C2 (uk) Інгібітори бромдомену
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MX2014012695A (es) Derivados de isoindolona.
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA38240A1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
UA107455C2 (uk) Похідні індолу як протиракові агенти
TR201819805T4 (tr) Flavaglin türevleri̇.
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines